ECHODYNE
15.4.2024 09:01:30 CEST | Business Wire | Press release
Echodyne, the radar platform company, is excited to announce it will be addressing the second annual Counter UAS Technology Europe 2024 conference, taking place at the Marriott Hotel Grosvenor Square in London over April 16-17, 2024. Echodyne VP of Marketing, Leo McCloskey, will discuss important counter-UAS developments in accuracy and mobility. Echodyne’s participation in this year’s event comes on the heels of significantly expanding its footprint in the region with new, European-based team members.
The conference is hosted by SAE Media Group and focuses on gathering European C-UAS stakeholders to address the growing proliferation of small drones and unmanned aircraft system (UAS) technology and the need for European armed forces and security agencies to protect critical national infrastructure and personnel at home and abroad by way of cutting-edge, C-UAS operations.
Drones are an increasing threat beyond the battlefield with payload and operational capabilities that challenge existing sensors and systems. From low, slow, and very effective small UAS to larger Group 3 UAS, the threat to logistics, missions, and warfighters is vast and expanding. Part of the challenge is sensors that can accurately track and deliver precise airspace coordinates of the intruding UAS, for which Echodyne’s metamaterials electronically scanned array (MESA®) are uniquely capable.
Cost symmetry is another challenge, with non-state actors spending small amounts on UAS weapons that require multi-million dollar systems to defeat. Echodyne’s radars achieve the optimal balance of low-cost, commercial off-the-shelf (COTS) advanced technology and high-performance, active beamforming ESA precision to create the most powerful, low-SWaP radars on the market. With both processed and unprocessed data integration options, Echodyne radars generate the most accurate data for detecting, tracking, targeting, and mitigating UAS threats.
“Solving the ‘drone problem’ requires technology and software that, when integrated, contributes high-fidelity, actionable data from attritable COTS platforms,” said Todd Fraser, Chief Revenue Officer at Echodyne. “Customer requirements are rapidly and radically changing, from fixed and portable to highly mobile, from crewed to uncrewed to platforms, from range as the sole driver to greater emphasis on spatial accuracy. Echodyne is expanding to meet increasing customer demand across Europe, Middle East, and Africa for low SWaP, commercially-exportable radars with superior ESA performance.”
Those interested in learning more about Echodyne’s radar for C-UAS operations, including remote weapons stations (RWS), short-range air defense (SHORAD) programs, and more are invited to attend Echodyne’s session at the Counter UAS Technology Europe 2024 Conference at 11 am BST on April 16, 2024. Those who are unable to attend can connect directly with a member of the Echodyne team here.
About Echodyne
Echodyne, the radar platform company, is a U.S. designer and manufacturer of advanced radar solutions for defense, government, and commercial market applications. The company’s proprietary metamaterials electronically scanned array (MESA®) architecture is a rare breakthrough in advanced radar engineering. Echodyne’s innovative MESA radars use standard materials and manufacturing processes to shatter unit cost barriers for high performance radar. The result is a solid-state, low-SWaP, exportable, commercial radar with advanced software capabilities that delivers superior performance, unparalleled data integrity, and exceptional situational awareness. Privately held, the company is backed by Bill Gates, NEA, Madrona Venture Group, Baillie Gifford, Northrop Grumman, and Supernal, among others. For more information, please visit: Echodyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415117922/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 07:00:00 CEST | Press release
World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2 At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at e
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
